In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: LifeStance Health trades near its PERT fair value of $10.70, implying 14% downside despite a DCF midpoint of $16.72, reflecting valuation uncertainty from poor profitability and high leverage. Monte Carlo analysis shows high volatility and significant downside risk, with a median value slightly below the current price. Liquidity is strong, but operational inefficiencies and leverage elevate investment risk.